Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges

8Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the joint lining. In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these.

Cite

CITATION STYLE

APA

Nicholson, T. A., Sagmeister, M., Wijesinghe, S. N., Farah, H., Hardy, R. S., & Jones, S. W. (2023, January 1). Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics15010237

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free